NRBO vs. AYTU, KPRX, EDSA, ABVC, TRAW, COCP, TLPH, NNVC, AVTX, and TNXP
Should you be buying NeuroBo Pharmaceuticals stock or one of its competitors? The main competitors of NeuroBo Pharmaceuticals include Aytu BioPharma (AYTU), Kiora Pharmaceuticals (KPRX), Edesa Biotech (EDSA), ABVC BioPharma (ABVC), Traws Pharma (TRAW), Cocrystal Pharma (COCP), Talphera (TLPH), NanoViricides (NNVC), Avalo Therapeutics (AVTX), and Tonix Pharmaceuticals (TNXP). These companies are all part of the "pharmaceutical preparations" industry.
NeuroBo Pharmaceuticals (NASDAQ:NRBO) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, community ranking, dividends, profitability and media sentiment.
Aytu BioPharma has a consensus price target of $5.00, indicating a potential upside of 76.06%. Given Aytu BioPharma's higher probable upside, analysts plainly believe Aytu BioPharma is more favorable than NeuroBo Pharmaceuticals.
NeuroBo Pharmaceuticals has higher earnings, but lower revenue than Aytu BioPharma.
NeuroBo Pharmaceuticals has a net margin of 0.00% compared to Aytu BioPharma's net margin of -18.27%. Aytu BioPharma's return on equity of -41.00% beat NeuroBo Pharmaceuticals' return on equity.
Aytu BioPharma received 229 more outperform votes than NeuroBo Pharmaceuticals when rated by MarketBeat users. However, 74.29% of users gave NeuroBo Pharmaceuticals an outperform vote while only 67.11% of users gave Aytu BioPharma an outperform vote.
NeuroBo Pharmaceuticals has a beta of -0.25, indicating that its stock price is 125% less volatile than the S&P 500. Comparatively, Aytu BioPharma has a beta of -1.21, indicating that its stock price is 221% less volatile than the S&P 500.
1.4% of NeuroBo Pharmaceuticals shares are held by institutional investors. Comparatively, 33.5% of Aytu BioPharma shares are held by institutional investors. 0.8% of NeuroBo Pharmaceuticals shares are held by insiders. Comparatively, 4.3% of Aytu BioPharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, NeuroBo Pharmaceuticals had 4 more articles in the media than Aytu BioPharma. MarketBeat recorded 5 mentions for NeuroBo Pharmaceuticals and 1 mentions for Aytu BioPharma. NeuroBo Pharmaceuticals' average media sentiment score of 0.24 beat Aytu BioPharma's score of 0.00 indicating that NeuroBo Pharmaceuticals is being referred to more favorably in the media.
Summary
Aytu BioPharma beats NeuroBo Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
Get NeuroBo Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for NRBO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NRBO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NeuroBo Pharmaceuticals Competitors List
Related Companies and Tools
